Veiga Glaucia Luciano da, Silva Raissa Daniel Machado da, Pereira Edimar Cristiano, Azzalis Ligia Ajaime, Alves Beatriz da Costa Aguiar, Gehrke Flavia de Sousa, Gascón Thaís Moura, Fonseca Fernando Luiz Affonso
Department fo Clinical Analysis - Medical School of ABC - FMABC - Santo André, SP, Brasil.
Faculty of Pharmaceutical Sciences - Federal University of São Paulo - Unifesp, Diadema, SP, Brasil.
Rev Assoc Med Bras (1992). 2019 Jul 22;65(6):893-901. doi: 10.1590/1806-9282.65.6.893.
Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.
乳腺癌（BC）是全球主要的健康问题之一。作为全球及巴西女性中最常见的癌症，仅次于非黑色素瘤皮肤癌，这种肿瘤约占该国每年新发病例的28%。乳腺癌也会影响男性，尽管其发病率仅占总病例的1%。目前，用于乳腺癌治疗的大多数化疗药物毒性极大，并会导致长期副作用。此外，还需要更早地进行诊断、做出更准确的预后评估，并提供更具选择性和有效性的新疗法，以改善当前的状况。因此，本研究旨在通过详细阐述生存素（Sur）作为生物标志物的作用、该蛋白与乳腺癌患者预后的相关性，以及针对Sur开发新抗癌疗法的治疗策略总结，来评估生物标志物Sur在乳腺癌中的重要性。
